Related Experiment Video
Updated: Aug 9, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[Molecular diagnosis of solid tumors]
1Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 19, 2005
Summary
This review covers three targeted cancer therapies approved in Japan: Trastuzumab for HER2-positive breast cancer, Imatinib for c-Kit-positive gastrointestinal tumors, and Gefitinib for non-small cell lung cancer linked to EGFR mutations. Diagnostic tools are crucial for successful molecular targeted therapy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Diagnostics
Background:
- Targeted therapeutics represent a significant advancement in cancer treatment.
- Precision medicine relies on identifying specific molecular targets within tumors.
- The approval of novel targeted drugs necessitates robust diagnostic strategies.
Purpose of the Study:
- To review three approved molecular targeted therapies for solid tumors in Japan.
- To highlight the importance of diagnostic tools in the application of targeted therapies.
- To discuss the methods and interpretation of diagnostic tests for these therapies.
Main Methods:
- Review of approved targeted therapeutics in Japan.
- Analysis of diagnostic methods for specific molecular targets (HER2/neu, c-Kit, EGFR mutations).
- Discussion of the clinical significance of diagnostic test results.
Main Results:
- Trastuzumab (Herceptin) approved for HER2/neu-overexpressing metastatic breast cancer.
- Imatinib mesylate (Gleevec) approved for c-Kit-expressing gastrointestinal tumors.
- Gefitinib (Iressa) approved for advanced non-small cell lung cancer, with response linked to EGFR mutations.
Conclusions:
- Molecular targeted therapies offer new treatment options for solid tumors.
- Accurate diagnostic tools are essential for patient selection and treatment success.
- The interpretation of diagnostic tests is critical for effective personalized cancer care.
